Discussion
T2D, hypoglycemia, atherosclerosis, T2DM, dyslipidemia
HYPOGLYCEMIA, ATHEROSCLEROSIS, DYSLIPIDEMIA
This study aimed to evaluate the efficacy and safety of beinaglutide in treatment of T2D. After 6 months, HbA1c decreased in both groups relative to baseline and the beinaglutide group had significant reductions in 2hBG compared with the control group. The LBGI of the test group was significantly lower than that of the control group, and no patient experienced hypoglycemia in the test group, suggesting that beinaglutide offered a treatment option that improved glycemic control with a low risk of hypoglycemia. Similar results were obtained in the study by Gao, Lijun et al. (Beinaglutide is a recombinant human GLP-1 analog with an identical amino acid sequence to native human GLP-1 (Clinical indicators of the patient with treatment-emergent beinaglutide ADAs.Postprandial elevated lipid levels are a significant aspect of dyslipidemia in patients with T2DM and are linked to atherosclerosis (Our study had some limitations. Firstly, it was a randomized but not a placebo controlled trial. Secondly, it is a non-multicenter, non-double-blind study with a short follow-up time. Thirdly, only the ADAs of beinaglutide in the test group were tested, and the number of subjects was relatively small. All of this might have significantly affected the quality of the data.